Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | CCR1 | P32246 | 3/20 | 0.61 |
| ▸ | CCR5 | P51681 | 3/20 | 0.61 |
| ▸ | CCR8 | P51685 | 3/20 | 0.61 |
| ▸ | P4HTM | Q9NXG6 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | METAP1 | P53582 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30510747 | 0.88 | TP53 (0.67) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL25292599 | 0.88 | TP53 (0.67) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL22043793 | 0.84 | NPC1 (0.46) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL4390590 | 0.83 | CCR1 (0.46) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL163378 | 0.79 | KDM4E (0.78) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL29907716 | 0.78 | KDM4E (1.00) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL5922 | 0.78 | KDM4E (1.00) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL29351528 | 0.78 | KDM4E (1.00) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL3711450 | 0.78 | KDM4E (1.00) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL21636881 | 0.77 | KDM4E (0.67) | KDM4ELMNACCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020116875-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME | 두산솔루스 주식회사 | 2020-06-11 | — | — | WO | disclosed |
| EP-2736338-B1 | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME (US) | 2019-01-23 | — | — | EP | disclosed |
| US-8084608-B2 | 2,2′ -bipyridine derivative having a reactive silyl group, its production method, and transition metal complex | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-20090299068-A1 | 2,2' -BIPYRIDINE DERIVATIVE HAVING A REACTIVE SILYL GROUP, ITS PRODUCTION METHOD, AND TRANSITION METAL COMPLEX | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2009-12-03 | — | — | US | disclosed |
| EP-2128165-A1 | 2, 2´-bipyridine derivatives having reactive silyl group, production methods, transition metal complexes thereof | Shin-Etsu Chemical Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299068-A1 | 2,2' -BIPYRIDINE DERIVATIVE HAVING A REACTIVE SILYL GROUP, ITS PRODUCTION METHOD, AND TRANSITION METAL COMPLEX | CBR3, TST, HRH3 | KDM4E 3085/4885LMNA 4659/4885CCR1 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.